{
  "schemaVersion": 1,
  "id": "research-184",
  "slug": "184-why-the-large-serelaxin-trial-did-not-confirm-a-benefit-in-acute-heart-failure",
  "title": "Why the Large Serelaxin Trial Did Not Confirm a Benefit in Acute Heart Failure",
  "catalogLabel": "Human Relaxin-2",
  "productCollection": "https://heritagebiolabs.com/research-library/products/human-relaxin-2",
  "productHandles": [
    "human-relaxin-2-588",
    "human-relaxin-2-562"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/human-relaxin-2-588",
    "https://heritagebiolabs.com/product/human-relaxin-2-562"
  ],
  "readingFocus": "Interpreting evidence",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 329,
  "sourceYears": [
    2019,
    2026
  ],
  "paragraphs": [
    "Peptides are short amino-acid chains connected by peptide bonds. Some circulate as hormones and influence blood flow or the way organs respond to changes in demand. Human relaxin-2 is a peptide hormone involved in cardiovascular and renal adaptations during pregnancy. Serelaxin is a recombinant form of human relaxin-2. Its effects on blood vessels provided a reason to test it in acute heart failure, when a person is hospitalized with worsening symptoms such as shortness of breath and fluid congestion. The older RELAX-AHF-2 trial is the direct human test of that question. [1]",
    "Marco Metra and colleagues reported results for 6,545 participants in a randomized, double-blind comparison. Both groups received standard care. One also received serelaxin and the other a placebo. The team selected two primary outcomes in advance: cardiovascular death by 180 days and worsening heart failure by day five. The first tested a longer-term outcome and the second a near-term deterioration during an acute episode. Setting those outcomes in advance gave readers a clear basis for deciding whether the main hypothesis was supported. [1]",
    "Cardiovascular death occurred in 8.7 percent of the serelaxin group and 8.9 percent of the placebo group. Worsening heart failure by day five occurred in 6.9 and 7.7 percent, respectively. The differences did not reach statistical significance, and the estimated ranges of plausible effects did not exclude no difference. The researchers also reported similar overall adverse-event incidence in the two groups. The trial did not demonstrate benefit on either primary outcome. [1]",
    "In 2026, a separate study observed effects of serelaxin on fibrotic changes in mouse models. That is a useful mechanistic result with a different endpoint and setting. It does not overturn the randomized comparison in hospitalized people. It also cannot show which patients might respond differently without new direct evidence. The two papers can coexist: a molecule can affect tissue biology in an experimental model while failing to improve the specified clinical outcomes under the conditions of a large trial. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Metra M et al. Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine (2019-08-22).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31433919/"
    },
    {
      "number": 2,
      "citation": "Wang Z et al. Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease. Life Sciences (online 2026-05-22).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42176886/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/184-why-the-large-serelaxin-trial-did-not-confirm-a-benefit-in-acute-heart-failure",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/184-why-the-large-serelaxin-trial-did-not-confirm-a-benefit-in-acute-heart-failure.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/184-why-the-large-serelaxin-trial-did-not-confirm-a-benefit-in-acute-heart-failure.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 037 - Hexarelin and Human Relaxin-2.docx",
    "sourceArticleNumber": 184,
    "contentSha256": "0aac27036d5a1b18f22fdec7cf22abf864e9b2e29cd3fdc7cc028cc05069b7f9",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
